Literature DB >> 16156096

Applications of the universal DNA microarray in molecular medicine.

Reyna Favis1, Norman P Gerry, Yu-Wei Cheng, Francis Barany.   

Abstract

Integration of molecular medicine into standard clinical practice will require the availability of diagnostics that are sensitive, rapid, and robust. The backbone technology underlying the diagnostic will likely serve double duty during clinical trials in order to first validate the biomarkers that contribute to both drug response and disease stratification. PCR/LDR/Universal DNA microarray is a promising technology to help drive the transition from the current paradigms of clinical decision making to the new era of personalized medicine. By uncoupling the mutation detection step from array hybridization, this technology becomes fully programmable. It exploits full use of the sensitivity that the ligase detection reaction can provide, while maintaining a rapid read out on a universal microarray. Thus, PCR/LDR/Universal DNA microarray is 50-fold more sensitive and 10-fold more rapid than conventional hybridization-only arrays. The intent of this article is to provide investigators with a perspective on current uses of this approach, as well as to serve as a practical guide to implementation.

Mesh:

Year:  2005        PMID: 16156096     DOI: 10.1385/1-59259-923-0:25

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  7 in total

1.  PCR/LDR/universal array platforms for the diagnosis of infectious disease.

Authors:  Maneesh Pingle; Mark Rundell; Sanchita Das; Linnie M Golightly; Francis Barany
Journal:  Methods Mol Biol       Date:  2010

2.  Development of an internal positive control for rapid diagnosis of avian influenza virus infections by real-time reverse transcription-PCR with lyophilized reagents.

Authors:  Amaresh Das; Erica Spackman; Dennis Senne; Jan Pedersen; David L Suarez
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

3.  Development of multiplex PCR-ligase detection reaction assay for detection of West Nile virus.

Authors:  S Rondini; M R Pingle; S Das; R Tesh; M S Rundell; J Hom; S Stramer; K Turner; S N Rossmann; R Lanciotti; E G Spier; J Muñoz-Jordán; D Larone; E Spitzer; F Barany; L M Golightly
Journal:  J Clin Microbiol       Date:  2008-05-21       Impact factor: 5.948

4.  SCN9A Variants May be Implicated in Neuropathic Pain Associated With Diabetic Peripheral Neuropathy and Pain Severity.

Authors:  Qingqin S Li; Peter Cheng; Reyna Favis; Alan Wickenden; Gary Romano; Hao Wang
Journal:  Clin J Pain       Date:  2015-11       Impact factor: 3.442

5.  BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.

Authors:  Maarten Timmers; Soraia Barão; Bianca Van Broeck; Ina Tesseur; John Slemmon; Katja De Waepenaert; Jennifer Bogert; Leslie M Shaw; Sebastiaan Engelborghs; Dieder Moechars; Marc Mercken; Luc Van Nueten; Luc Tritsmans; Bart de Strooper; Johannes Rolf Streffer
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors.

Authors:  Bianca Van Broeck; Maarten Timmers; Steven Ramael; Jennifer Bogert; Leslie M Shaw; Marc Mercken; John Slemmon; Luc Van Nueten; Sebastiaan Engelborghs; Johannes Rolf Streffer
Journal:  Alzheimers Res Ther       Date:  2016-05-19       Impact factor: 6.982

7.  Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor.

Authors:  Maarten Timmers; Bianca Van Broeck; Steven Ramael; John Slemmon; Katja De Waepenaert; Alberto Russu; Jennifer Bogert; Hans Stieltjes; Leslie M Shaw; Sebastiaan Engelborghs; Dieder Moechars; Marc Mercken; Enchi Liu; Vikash Sinha; John Kemp; Luc Van Nueten; Luc Tritsmans; Johannes Rolf Streffer
Journal:  Alzheimers Dement (N Y)       Date:  2016-08-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.